Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Relapse may contribute to antipsychotic treatment resistance

03 Dec 2018

Relapse following effective treatment of the first episode of schizophrenia may reduce or delay antipsychotic treatment response, a recent study has shown.

Patients with a diagnosis of first-episode schizophrenia or schizoaffective disorder who met the following criteria were included: referral to the First-Episode Psychosis Program between 2003 and 2013; treatment with an oral second-generation antipsychotic according to a standardized treatment algorithm; positive symptom remission; subsequent relapse (ie, second episode) in association with nonadherence; and reintroduction of antipsychotic treatment with the same agent used to achieve response in the first episode.

Outcomes used as an index of antipsychotic treatment response were as follows: changes in the brief psychiatric rating scale total and positive symptom scores and number of patients who achieved positive symptom remission and 20- and 50-percent response.

One hundred thirty patients were analysed, and all of them took the same antipsychotic drug in both episodes. However, significant episode-by-time interactions occurred for all outcomes of antipsychotic treatment response over 1 year in favour of the first vs the second episode (50-percent response rate: 48.7 percent vs 10.4 percent at week 7; 88.2 percent vs 27.8 percent at week 27, respectively).

There were significantly higher antipsychotic doses in the second vs the first episode, but the results remained unchanged after adjusting for antipsychotic dose.

“Although some studies have suggested that relapse may be associated with antipsychotic treatment resistance in schizophrenia, the number and quality of studies is limited,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.